Prion Protein Expressing Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Prion protein-expressing neurons represent a unique population of cells that naturally produce the cellular prion protein (PrPC), a glycosylphosphatidylinositol (GPI)-anchored protein implicated in neurodegeneration when misfolded into the disease-causing isoform (PrPSc). These neurons are central to understanding prion diseases, which include Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), and bovine spongiform encephalopathy (BSE).
| Property |
Value |
| Gene |
PRNP (prion protein gene) |
| Protein |
PrPC (cellular prion protein) |
| Location |
Chromosome 20p13 |
| Expression |
Neurons, astrocytes, microglia |
| Function |
Neuroprotection, copper binding, synaptic function |
The PRNP gene encodes the cellular prion protein, a 253-amino acid GPI-anchored protein:
- Signal peptide: Residues 1-22 (secretory signal)
- Prion domain: Residues 23-144 (contains octapeptide repeats)
- C-terminal domain: Residues 145-231 (contains three α-helices and two β-strands)
- GPI anchor: Residues 232-253 (membrane attachment)
PrPC performs several physiological roles:
Neuroprotection:
- Anti-apoptotic properties through Bcl-2 interaction
- Copper ion binding and homeostasis
- Antioxidant activity via superoxide dismutase-like function
Synaptic Function:
- Synaptic vesicle release modulation
- Neuronal excitability regulation
- Synaptic plasticity involvement
Cell Signaling:
- PrPC forms complexes with various membrane proteins
- Activates neuroprotective signaling cascades
- Modulates neurite outgrowth and neuronal differentiation
PrPC is expressed throughout the central nervous system with regional variation:
- Cerebellum: High expression in Purkinje cells and granule cells
- Hippocampus: Prominent in CA1-CA3 pyramidal neurons
- Cortex: Layer V pyramidal neurons show strong expression
- Brainstem: Moderate expression in cranial nerve nuclei
- Spinal cord: Motor neurons and interneurons express PrPC
- Olfactory bulb: High expression in mitral and tufted cells
The conversion of PrPC to PrPSc represents a conformational change:
- α-helices convert to β-sheet structures
- Protein becomes protease-resistant
- Forms insoluble aggregates
- Exhibits infectious properties
Certain neurons are particularly susceptible to prion toxicity:
Highly Vulnerable:
- Cerebellar Purkinje cells (early loss in CJD)
- Cortical pyramidal neurons (spongiform changes)
- Hippocampal CA1 neurons (memory impairment)
Mechanisms:
Cellular Pathways Affected:
- Proteostasis failure: Impaired protein quality control
- Oxidative stress: ROS accumulation and neuronal damage
- Calcium dysregulation: Homeostasis disruption
- Neuroinflammation: Microglial activation
- Synaptic dysfunction: Early synaptic loss
PrPC neurons are directly implicated in CJD pathogenesis:
- Prion deposition in neurons and neuropil
- Spongiform degeneration of gray matter
- Neuronal loss in cortex and cerebellum
- Variant CJD involves tonsillar tissue with PrPSc
FFI specifically targets thalamic neurons:
- Dorsomedial nucleus of thalamus most affected
- Insomnia due to thalamocortical disconnection
- Autonomic dysfunction from hypothalamic involvement
- PRNP D178N mutation causes familial cases
- Cerebellar ataxia as presenting symptom
- Plaque formation in cerebellum and cerebral cortex
- PRNP point mutations cause genetic susceptibility
- ** Forebrain neurons** affected in Papua New Guinea populations
- Chronic infection with prolonged incubation
- Demonstrates person-to-person transmission
- PrPC knockout neurons: N2a neuroblastoma cells with PRNP deletion
- Prion-infected neuronal cultures: Chronic prion exposure models
- iPSC-derived neurons: Patient-specific models for disease mechanisms
- PRNP knockout mice: Comprehensive phenotypic analysis
- Transgenic PrP models: Human PRNP expression and mutation studies
- Prion-infected mice: Inoculation models for disease progression
- Zebrafish models: Developmental studies of PrP function
- PrPSc formation assays: In vitro conversion systems
- Cell-based screens: Compounds preventing prion replication
- Organotypic slice cultures: Drug efficacy testing
Several approaches target PrPC neurons:
Small Molecules:
- Quinacrine: Autophagy induction and PrPSc clearance
- Pentosan polysulfate: CNS penetration and anti-prion activity
- Brilacidin: Antimicrobial peptide with anti-prion properties
Antibody Approaches:
- Anti-PrP antibodies for passive immunization
- Antibody fragments penetrating the CNS
- Engineered bispecific antibodies
- RNAi approaches: Reduce PrPC expression
- CRISPR editing: Correct disease-causing mutations
- Antisense oligonucleotides: Targeted mRNA degradation
- Quinacrine evaluated in clinical trials for CJD (2007-2013)
- Doxycycline showed promise in retrospective analysis
- Anti-PrP antibodies in preclinical development
¶ Diagnosis and Biomarkers
- MRI: Cortical ribboning, basal ganglia hyperintensities in CJD
- PET: Reduced glucose metabolism in affected regions
- SPECT: Perfusion deficits in thalamus (FFI)
- 14-3-3 protein: Neuronal damage marker
- Tau protein: Elevated in prion diseases
- PrPSc: Detection by RT-QuIC assay
The study of Prion Protein Expressing Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.